证券代码：603456 证券简称：九洲药业 公告编号：2024-079 浙江九洲药业股份有限公司 关于注销部分已回购股份的实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：浙江九洲药业股份有限公司（以下简称"公司"）分别于 2024 年 8 月 26 日、9 月 18 日召开第八届董事会第九次会议、2024 年第一次临 时股东大会，审议通过《关于变更回购股份用途并注销的议案》，同意公司将 2022 年股份回购方案用途由"用于后续实施股权激励计划"变更为"用于注销并减少 公司注册资本"，即对回购专用证券账户中 2022 年股份回购方案的 2,871,000 股 库存股进行注销并相应减少注册资本。 本次注销股份的有关情况 | 回购专用证券账户 | 本次注销 | 注销日期 | | | | | --- | --- | --- | --- | --- | --- | | 股份数量（股） | 股份数量（股） | | | | | | 8,660,800 | 2,871,000 | 年 2024 | 11 ...

浙江天册律师事务所 关于 浙江九洲药业股份有限公司 回购注销限制性股票实施之 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 邮编 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于浙江九洲药业股份有限公司 回购注销限制性股票实施之 法律意见书 编号：TCYJS2024H1775号 致：浙江九洲药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江九洲药业股份有限公司 （以下简称"公司"或"九洲药业"）的委托，就公司实施 2022 年限制性股票 激励计划（以下简称"本次激励计划"）有关事项担任专项法律顾问，并依据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）等有关法律、法规和规范性文件及九洲药业《公司章程》的相关规 定，已出具了 TCYJS2022H0230 号《浙江天册律师事务所关于浙江九洲药业股份 有限公司 2022 年限制性股票激励计划的法律意见书》、TCYJS2022H0291 号《浙 ...

浙江天册律师事务所 关于 浙江九洲药业股份有限公司 回购注销限制性股票实施之 法律意见书 浙江天册律师事务所 关于浙江九洲药业股份有限公司 回购注销限制性股票实施之 法律意见书 编号：TCYJS2024H1776号 致：浙江九洲药业股份有限公司 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 邮编 310007 电话：0571-87901111 传真：0571-87901500 浙江天册律师事务所（以下简称"本所"）接受浙江九洲药业股份有限公司 （以下简称"公司"或"九洲药业"）的委托，就公司实施 2021 年限制性股票 激励计划（以下简称"本次激励计划"）有关事项担任专项法律顾问，并依据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）等有关法律、法规和规范性文件及九洲药业《公司章程》的相关规 定，已出具了 TCYJS2021H0711 号《浙江天册律师事务所关于浙江九洲药业股份 有限公司 2021 年限制性股票激励计划的法律意见书》、TCYJS2021H0831 号《浙 ...

证券代码：603456 证券简称：九洲药业 公告编号：2024-078 浙江九洲药业股份有限公司 股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：受到市场环境等多方面因素发生显著变化的影响，浙江 九洲药业股份有限公司（以下简称"公司"）继续实施 2021 年、2022 年股权激励 计划将难以达到预期的激励目的和激励效果；在统筹考虑业务发展实际情况以及 股权激励相关工作整体安排基础上，为更好地维护公司、股东和员工的利益，根 据《上市公司股权激励管理办法》、《2021 年限制性股票激励计划（草案）》、《2022 年限制性股票激励计划（草案）》等相关法律规定，经审慎考虑，公司决定终止 2021 年、2022 年限制性股票激励计划，所涉已获授但尚未解除限售的 1,328,400 股限制性股票需由公司回购注销。 受到市场环境等多方面因素发生显著变化的影响，公司继续实施 2021 年、 2022 年股权激励计划将难以达到预期的激励目的和激励效果；在统筹考虑业务 发展实际情况 ...

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company's performance is under short-term pressure, with a significant decline in revenue and net profit in Q3 2024 compared to the previous year [1] - Despite the short-term challenges, the CDMO (Contract Development and Manufacturing Organization) business is experiencing continuous growth in overseas new projects, particularly in the ADC (Antibody-Drug Conjugates) and peptide sectors [2] - The API (Active Pharmaceutical Ingredients) business faces intensified market competition, prompting the company to accelerate the integration of raw material and formulation processes [3] Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved revenue of 39.65 billion yuan, down 13.36% year-over-year, and a net profit of 6.31 billion yuan, down 34.74% year-over-year [1] - In Q3 2024, revenue was 12.01 billion yuan, a decrease of 9.15% year-over-year, with a net profit of 1.56 billion yuan, down 54.82% year-over-year [1] - The gross margin for Q3 2024 was 33.68%, a decline of 7.86 percentage points year-over-year, and the net profit margin was 12.98%, down 13.12 percentage points year-over-year [1] CDMO Business - In H1 2024, the CDMO business generated revenue of 19.71 billion yuan, a decrease of 20.61% year-over-year, but the gross margin improved slightly to 41.06% [2] - The company saw a 15% year-over-year increase in the number of new projects, with over half of these projects coming from overseas clients [2] - The company has established a TIDES division to focus on peptide and ADC businesses, with plans to build six GMP production lines for peptides over the next five years [2] API Business - The API business reported revenue of 7.32 billion yuan in H1 2024, an increase of 5.54% year-over-year, but faced significant declines in revenue and gross margin in Q3 due to increased competition [3] - The company is optimizing its product structure and upgrading existing products to enhance profitability in the API segment [3] - As of June 2024, the company has reserved 22 generic drug formulation projects, with four approved and six submitted for market approval [3] Earnings Forecast and Valuation - The forecast for the company's net profit for 2024 and 2025 has been revised down to 8.84 billion yuan and 9.90 billion yuan, respectively, reflecting a reduction of 44% and 50% from previous estimates [3] - The estimated EPS for 2024, 2025, and 2026 is projected to be 0.98 yuan, 1.10 yuan, and 1.26 yuan, respectively, with corresponding PE ratios of 17, 15, and 13 times [3]

证券时报e公司讯，九洲药业(603456)10月31日晚间公告，控股子公司康川济医药收到国家药监局核准 签发的盐酸多巴胺注射液的《药品注册证书》。 盐酸多巴胺注射液，适用于心肌梗死、创伤、内毒素败血症、心脏手术、肾功能衰竭、充血性心力衰竭 等引起的休克综合征；补充血容量后休克仍不能纠正者，尤其有少尿及周围血管阻力正常或较低的休 克。 ...

证券代码：603456 证券简称：九洲药业 公告编号：2024-077 浙江九洲药业股份有限公司 关于控股子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 剂型：注射剂 规格：2.5ml：50mg 申请事项：药品注册（境内生产） 注册分类：化学药品 3 类 批准文号：国药准字 H20249144 上市许可持有人：南京康川济医药科技有限公司 上市许可持有人地址：南京市江宁区文芳路 199 号 5 幢二层（江宁高新园） 近日，浙江九洲药业股份有限公司（以下简称"公司"）控股子公司南京康 川济医药科技有限公司（以下简称"康川济医药"）收到国家药品监督管理局（以 下简称"国家药监局"）核准签发的盐酸多巴胺注射液的《药品注册证书》（受理 号：CYHS2301483），具体情况如下： 一、药品的基本情况 药品名称：盐酸多巴胺注射液 三、对上市公司的影响及风险提示 本次取得盐酸多巴胺注射液的《药品注册证书》，表明康川济医药可在国内 市场生产、销售该药品，进一步丰富公司产品管线，有助于提升公司产品的市场 竞争力。上 ...

Financial Performance - In the first three quarters of 2024, the company achieved revenue of 3.965 billion CNY, a year-on-year decrease of 13.36% [3] - The net profit attributable to the parent company was 631 million CNY, down 34.74% year-on-year [3] - The company experienced a narrowing decline in quarterly revenue, with stable performance from major clients and significant growth in the formulation business [3] Business Development - The company is enhancing its R&D platform and expanding its global business by establishing wholly-owned subsidiaries in Japan and Germany [2][3] - New project numbers increased by 15% year-on-year, with over half of new projects coming from overseas, particularly in the European market [3][4] - The CDMO business showed steady growth in Q3, with expectations for continued improvement in Q4, maintaining an annual gross margin around 40% [4] Capacity and Production - The new base in Taizhou is progressing with the construction of four workshops, with a current capacity utilization rate of 30-40% [4] - The overall capacity utilization rate is below 60%, primarily affected by the specialty raw materials business [6] - The company plans to establish six peptide GMP production lines within five years, aiming for an annual production capacity of 2-3 tons of peptide products [5] Market Challenges and Strategies - The specialty raw materials segment faced significant revenue and gross margin declines due to market competition and price fluctuations [6] - The company is implementing strategic product adjustments and increasing R&D investment to enhance cost competitiveness [6] - The company is actively expanding its overseas business development team and establishing R&D platforms in the US, Japan, and Germany to drive new client acquisition [5][7] Future Outlook - The company is pursuing overseas capacity acquisitions, focusing on Europe and North America, with an expected acquisition amount not exceeding 100 million USD [7] - The formulation business is expected to maintain high growth throughout the year, supported by recent acquisitions and the establishment of a complete industry chain [7]

股 票 研 究 证 券 研 究 报 告 ——九洲药业 2024 年三季报点评 原料药承压，新业务加码推进 九洲药业(603456) [Table_Industry] 医药/必需消费 | --- | --- | --- | --- | --- | --- | |----------|-----------------------------------|-----------------------|-------|-------|-------| | | | | | | | | | [table_Authors] 丁丹 ( 分析师 ) | 吴晗 ( 分析师 ) | | | | | | 0755-23976735 | 010-83939773 | | | | | | dingdan@gtjas.com | wuhan024878@gtjas.com | | | | | 登记编号 | S0880514030001 | S0880523080005 | | | | 本报告导读： 原料药短期承压，制剂布局加快，多肽等新兴业务加码布局，业绩增长可期。 投资要点： [Table_Summary] 维持"增持"评级。202 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing temporary pressure on its Q3 performance, with a focus on actively advancing new business areas [3] - Despite a decline in revenue and net profit, the company's CDMO business remains stable, and the rapid development of its peptide business is expected to contribute to new revenue growth [3] Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 3.965 billion yuan, a year-on-year decline of 13.36%; net profit attributable to shareholders was 631 million yuan, down 34.74% year-on-year; and net profit excluding non-recurring items was 618 million yuan, down 35.04% year-on-year [3] - In Q3 alone, revenue was 1.201 billion yuan, a year-on-year decline of 9.15% and a quarter-on-quarter decline of 6.79%; net profit attributable to shareholders was 156 million yuan, down 54.80% year-on-year and 34.56% quarter-on-quarter [3] - The company has adjusted its profit forecast for 2024-2026, expecting net profits of 854 million, 972 million, and 1.181 billion yuan respectively, with corresponding EPS of 0.95, 1.08, and 1.31 yuan [3] Business Development Summary - The company's raw material CDMO project pipeline is steadily growing, with a 14% year-on-year increase in new projects in H1 2024, totaling 1,103 projects by the end of June 2024 [4] - The company is actively expanding its formulation CDMO business, serving over 60 clients with more than 100 formulation projects, and has seen a project number increase of approximately 32% year-on-year, with revenue growth exceeding 50% [4] - The establishment of the TIDES division in H1 2024 aims to accelerate the development of new business areas, particularly in peptide-conjugated drug technology [5]